APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Pain Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cancer Pain Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchCancer Pain Therapeutics Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Pain Therapeutics Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Cancer Pain Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Pain Therapeutics Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Pain Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Cancer Pain Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cancer Pain Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Pain Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Pain Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cancer Pain Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Pain Therapeutics include BioDelivery Science, Grunenthal Group, GW Pharmaceuticals, Meda Pharmaceuticals, Orexo, ProStrakan Group, WEX Pharmaceuticals, Eli-Lilly and Johnson＆Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Pain Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Pain Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Pain Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Pain Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Pain Therapeutics Segment by Company

BioDelivery Science

Grunenthal Group

GW Pharmaceuticals

Meda Pharmaceuticals

Orexo

ProStrakan Group

WEX Pharmaceuticals

Eli-Lilly

Johnson＆Johnson

Sanofi

Teva pharmaceuticals

Cancer Pain Therapeutics Segment by Type

Opioids

Non-Steroidal Anti-Inflammatory Drugs

Others

Cancer Pain Therapeutics Segment by Application

Hormone Therapy

Chemotherapy

Radiotherapy

Paracetamol Treatment-Related Immunotherapy

Cancer Pain Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Pain Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Pain Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Pain Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Pain Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Pain Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cancer Pain Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cancer Pain Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cancer Pain Therapeutics Industry Trends Table 2. Cancer Pain Therapeutics Industry Drivers Table 3. Cancer Pain Therapeutics Industry Opportunities and Challenges Table 4. Cancer Pain Therapeutics Industry Restraints Table 5. Global Cancer Pain Therapeutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cancer Pain Therapeutics Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cancer Pain Therapeutics Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Cancer Pain Therapeutics Sales Market Share by Manufacturers Table 9. Global Cancer Pain Therapeutics Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Cancer Pain Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cancer Pain Therapeutics Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cancer Pain Therapeutics Manufacturers, Product Type & Application Table 13. Global Cancer Pain Therapeutics Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Pain Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Opioids Table 17. Major Manufacturers of Non-Steroidal Anti-Inflammatory Drugs Table 18. Major Manufacturers of Others Table 19. Global Cancer Pain Therapeutics Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Cancer Pain Therapeutics Sales by Type (2021-2026) & (k units) Table 21. Global Cancer Pain Therapeutics Sales by Type (2027-2032) & (k units) Table 22. Global Cancer Pain Therapeutics Sales Market Share by Type (2021-2026) Table 23. Global Cancer Pain Therapeutics Sales Market Share by Type (2027-2032) Table 24. Global Cancer Pain Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Cancer Pain Therapeutics Revenue by Type (2021-2026) & (k units) Table 26. Global Cancer Pain Therapeutics Revenue by Type (2027-2032) & (k units) Table 27. Global Cancer Pain Therapeutics Revenue Market Share by Type (2021-2026) Table 28. Global Cancer Pain Therapeutics Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hormone Therapy Table 30. Major Manufacturers of Chemotherapy Table 31. Major Manufacturers of Radiotherapy Table 32. Major Manufacturers of Paracetamol Treatment-Related Immunotherapy Table 33. Global Cancer Pain Therapeutics Sales by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Cancer Pain Therapeutics Sales by Application (2021-2026) & (k units) Table 35. Global Cancer Pain Therapeutics Sales by Application (2027-2032) & (k units) Table 36. Global Cancer Pain Therapeutics Sales Market Share by Application (2021-2026) Table 37. Global Cancer Pain Therapeutics Sales Market Share by Application (2027-2032) Table 38. Global Cancer Pain Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 39. Global Cancer Pain Therapeutics Revenue by Application (2021-2026) & (k units) Table 40. Global Cancer Pain Therapeutics Revenue by Application (2027-2032) & (k units) Table 41. Global Cancer Pain Therapeutics Revenue Market Share by Application (2021-2026) Table 42. Global Cancer Pain Therapeutics Revenue Market Share by Application (2027-2032) Table 43. Global Cancer Pain Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Cancer Pain Therapeutics Sales by Region (2021-2026) & (k units) Table 45. Global Cancer Pain Therapeutics Sales Market Share by Region (2021-2026) Table 46. Global Cancer Pain Therapeutics Sales Forecasted by Region (2027-2032) & (k units) Table 47. Global Cancer Pain Therapeutics Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Cancer Pain Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 49. North America Cancer Pain Therapeutics Sales by Country (2021-2026) & (k units) Table 50. North America Cancer Pain Therapeutics Sales by Country (2027-2032) & (k units) Table 51. Europe Cancer Pain Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. Europe Cancer Pain Therapeutics Sales by Country (2021-2026) & (k units) Table 53. Europe Cancer Pain Therapeutics Sales by Country (2027-2032) & (k units) Table 54. Asia Pacific Cancer Pain Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Asia Pacific Cancer Pain Therapeutics Sales by Country (2021-2026) & (k units) Table 56. Asia Pacific Cancer Pain Therapeutics Sales by Country (2027-2032) & (k units) Table 57. South America, Middle East and Africa Cancer Pain Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. South America, Middle East and Africa Cancer Pain Therapeutics Sales by Country (2021-2026) & (k units) Table 59. South America, Middle East and Africa Cancer Pain Therapeutics Sales by Country (2027-2032) & (k units) Table 60. Global Cancer Pain Therapeutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Cancer Pain Therapeutics Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Cancer Pain Therapeutics Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Cancer Pain Therapeutics Revenue Market Share by Region (2021-2026) Table 64. Global Cancer Pain Therapeutics Revenue Market Share by Region (2027-2032) Table 65. BioDelivery Science Company Information Table 66. BioDelivery Science Business Overview Table 67. BioDelivery Science Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. BioDelivery Science Cancer Pain Therapeutics Product Portfolio Table 69. BioDelivery Science Recent Development Table 70. Grunenthal Group Company Information Table 71. Grunenthal Group Business Overview Table 72. Grunenthal Group Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Grunenthal Group Cancer Pain Therapeutics Product Portfolio Table 74. Grunenthal Group Recent Development Table 75. GW Pharmaceuticals Company Information Table 76. GW Pharmaceuticals Business Overview Table 77. GW Pharmaceuticals Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. GW Pharmaceuticals Cancer Pain Therapeutics Product Portfolio Table 79. GW Pharmaceuticals Recent Development Table 80. Meda Pharmaceuticals Company Information Table 81. Meda Pharmaceuticals Business Overview Table 82. Meda Pharmaceuticals Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Meda Pharmaceuticals Cancer Pain Therapeutics Product Portfolio Table 84. Meda Pharmaceuticals Recent Development Table 85. Orexo Company Information Table 86. Orexo Business Overview Table 87. Orexo Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Orexo Cancer Pain Therapeutics Product Portfolio Table 89. Orexo Recent Development Table 90. ProStrakan Group Company Information Table 91. ProStrakan Group Business Overview Table 92. ProStrakan Group Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. ProStrakan Group Cancer Pain Therapeutics Product Portfolio Table 94. ProStrakan Group Recent Development Table 95. WEX Pharmaceuticals Company Information Table 96. WEX Pharmaceuticals Business Overview Table 97. WEX Pharmaceuticals Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. WEX Pharmaceuticals Cancer Pain Therapeutics Product Portfolio Table 99. WEX Pharmaceuticals Recent Development Table 100. Eli-Lilly Company Information Table 101. Eli-Lilly Business Overview Table 102. Eli-Lilly Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Eli-Lilly Cancer Pain Therapeutics Product Portfolio Table 104. Eli-Lilly Recent Development Table 105. Johnson＆Johnson Company Information Table 106. Johnson＆Johnson Business Overview Table 107. Johnson＆Johnson Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Johnson＆Johnson Cancer Pain Therapeutics Product Portfolio Table 109. Johnson＆Johnson Recent Development Table 110. Sanofi Company Information Table 111. Sanofi Business Overview Table 112. Sanofi Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Sanofi Cancer Pain Therapeutics Product Portfolio Table 114. Sanofi Recent Development Table 115. Teva pharmaceuticals Company Information Table 116. Teva pharmaceuticals Business Overview Table 117. Teva pharmaceuticals Cancer Pain Therapeutics Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Teva pharmaceuticals Cancer Pain Therapeutics Product Portfolio Table 119. Teva pharmaceuticals Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Cancer Pain Therapeutics Distributors List Table 123. Cancer Pain Therapeutics Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Cancer Pain Therapeutics Product Image Figure 2. Global Cancer Pain Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Pain Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Pain Therapeutics Sales (2021-2032) & (k units) Figure 5. Global Cancer Pain Therapeutics Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cancer Pain Therapeutics Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Opioids Image Figure 9. Non-Steroidal Anti-Inflammatory Drugs Image Figure 10. Others Image Figure 11. Global Cancer Pain Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Cancer Pain Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Cancer Pain Therapeutics Sales Market Share by Type (2021-2032) Figure 14. Global Cancer Pain Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Cancer Pain Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Cancer Pain Therapeutics Revenue Market Share by Type (2021-2032) Figure 17. Hormone Therapy Image Figure 18. Chemotherapy Image Figure 19. Radiotherapy Image Figure 20. Paracetamol Treatment-Related Immunotherapy Image Figure 21. Global Cancer Pain Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Cancer Pain Therapeutics Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Cancer Pain Therapeutics Sales Market Share by Application (2021-2032) Figure 24. Global Cancer Pain Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Cancer Pain Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Cancer Pain Therapeutics Revenue Market Share by Application (2021-2032) Figure 27. North America Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 28. North America Cancer Pain Therapeutics Sales Market Share by Country (2021-2032) Figure 29. U.S. Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 30. Canada Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 31. Mexico Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Cancer Pain Therapeutics Sales Market Share by Country (2021-2032) Figure 34. Germany Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 35. France Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 36. U.K. Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 37. Italy Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 38. Netherlands Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Cancer Pain Therapeutics Sales Market Share by Country (2021-2032) Figure 41. China Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 42. Japan Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 43. South Korea Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 44. Southeast Asia Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 45. India Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 46. Australia Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Cancer Pain Therapeutics Sales Market Share by Country (2021-2032) Figure 49. Brazil Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 50. South Africa Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 51. Saudi Arabia Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 52. Turkey Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 53. Argentina Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 54. UAE Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 55. Egypt Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 56. Chile Cancer Pain Therapeutics Sales and Growth Rate (2021-2032) & (k units) Figure 57. Global Cancer Pain Therapeutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Cancer Pain Therapeutics Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Cancer Pain Therapeutics Revenue (2021-2032) & (US$ Million) Figure 60. North America Cancer Pain Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Cancer Pain Therapeutics Revenue (2021-2032) & (US$ Million) Figure 62. Europe Cancer Pain Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Cancer Pain Therapeutics Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Cancer Pain Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Cancer Pain Therapeutics Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Cancer Pain Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Cancer Pain Therapeutics Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Cancer Pain Therapeutics Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Opioids
  • Non-Steroidal Anti-Inflammatory Drugs
  • Others
Applications
  • Hormone Therapy
  • Chemotherapy
  • Radiotherapy
  • Paracetamol Treatment-Related Immunotherapy
Companies covered
  • BioDelivery Science
  • Grunenthal Group
  • GW Pharmaceuticals
  • Meda Pharmaceuticals
  • Orexo
  • ProStrakan Group
  • WEX Pharmaceuticals
  • Eli-Lilly
  • Johnson＆Johnson
  • Sanofi
  • Teva pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Pain Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Pain Therapeutics Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cancer Pain Therapeutics Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cancer Pain Therapeutics Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cancer Pain Therapeutics Market Dynamics
  1. 2.1 Cancer Pain Therapeutics Industry Trends
  2. 2.2 Cancer Pain Therapeutics Industry Drivers
  3. 2.3 Cancer Pain Therapeutics Industry Opportunities and Challenges
  4. 2.4 Cancer Pain Therapeutics Industry Restraints
3 Cancer Pain Therapeutics Market by Manufacturers
  1. 3.1 Global Cancer Pain Therapeutics Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cancer Pain Therapeutics Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cancer Pain Therapeutics Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cancer Pain Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Pain Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cancer Pain Therapeutics Manufacturers, Product Type & Application
  7. 3.7 Global Cancer Pain Therapeutics Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Pain Therapeutics Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Pain Therapeutics Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Pain Therapeutics Tier 1, Tier 2, and Tier 3
4 Cancer Pain Therapeutics Market by Type
  1. 4.1 Cancer Pain Therapeutics Type Introduction
  2. 4.1.1 Opioids
  3. 4.1.2 Non-Steroidal Anti-Inflammatory Drugs
  4. 4.1.3 Others
  5. 4.2 Global Cancer Pain Therapeutics Sales by Type
  6. 4.2.1 Global Cancer Pain Therapeutics Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Cancer Pain Therapeutics Sales by Type (2021-2032)
  8. 4.2.3 Global Cancer Pain Therapeutics Sales Market Share by Type (2021-2032)
  9. 4.3 Global Cancer Pain Therapeutics Revenue by Type
  10. 4.3.1 Global Cancer Pain Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Cancer Pain Therapeutics Revenue by Type (2021-2032)
  12. 4.3.3 Global Cancer Pain Therapeutics Revenue Market Share by Type (2021-2032)
5 Cancer Pain Therapeutics Market by Application
  1. 5.1 Cancer Pain Therapeutics Application Introduction
  2. 5.1.1 Hormone Therapy
  3. 5.1.2 Chemotherapy
  4. 5.1.3 Radiotherapy
  5. 5.1.4 Paracetamol Treatment-Related Immunotherapy
  6. 5.2 Global Cancer Pain Therapeutics Sales by Application
  7. 5.2.1 Global Cancer Pain Therapeutics Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Cancer Pain Therapeutics Sales by Application (2021-2032)
  9. 5.2.3 Global Cancer Pain Therapeutics Sales Market Share by Application (2021-2032)
  10. 5.3 Global Cancer Pain Therapeutics Revenue by Application
  11. 5.3.1 Global Cancer Pain Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Cancer Pain Therapeutics Revenue by Application (2021-2032)
  13. 5.3.3 Global Cancer Pain Therapeutics Revenue Market Share by Application (2021-2032)
6 Global Cancer Pain Therapeutics Sales by Region
  1. 6.1 Global Cancer Pain Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Pain Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Pain Therapeutics Sales by Region (2021-2026)
  4. 6.2.2 Global Cancer Pain Therapeutics Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Pain Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cancer Pain Therapeutics Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cancer Pain Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cancer Pain Therapeutics Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cancer Pain Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cancer Pain Therapeutics Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cancer Pain Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cancer Pain Therapeutics Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cancer Pain Therapeutics Revenue by Region
  1. 7.1 Global Cancer Pain Therapeutics Revenue by Region
  2. 7.1.1 Global Cancer Pain Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cancer Pain Therapeutics Revenue by Region (2021-2026)
  4. 7.1.3 Global Cancer Pain Therapeutics Revenue by Region (2027-2032)
  5. 7.1.4 Global Cancer Pain Therapeutics Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cancer Pain Therapeutics Revenue (2021-2032)
  8. 7.2.2 North America Cancer Pain Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cancer Pain Therapeutics Revenue (2021-2032)
  11. 7.3.2 Europe Cancer Pain Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cancer Pain Therapeutics Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cancer Pain Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cancer Pain Therapeutics Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cancer Pain Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 BioDelivery Science
  2. 8.1.1 BioDelivery Science Company Information
  3. 8.1.2 BioDelivery Science Business Overview
  4. 8.1.3 BioDelivery Science Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 BioDelivery Science Cancer Pain Therapeutics Product Portfolio
  6. 8.1.5 BioDelivery Science Recent Developments
  7. 8.2 Grunenthal Group
  8. 8.2.1 Grunenthal Group Company Information
  9. 8.2.2 Grunenthal Group Business Overview
  10. 8.2.3 Grunenthal Group Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Grunenthal Group Cancer Pain Therapeutics Product Portfolio
  12. 8.2.5 Grunenthal Group Recent Developments
  13. 8.3 GW Pharmaceuticals
  14. 8.3.1 GW Pharmaceuticals Company Information
  15. 8.3.2 GW Pharmaceuticals Business Overview
  16. 8.3.3 GW Pharmaceuticals Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GW Pharmaceuticals Cancer Pain Therapeutics Product Portfolio
  18. 8.3.5 GW Pharmaceuticals Recent Developments
  19. 8.4 Meda Pharmaceuticals
  20. 8.4.1 Meda Pharmaceuticals Company Information
  21. 8.4.2 Meda Pharmaceuticals Business Overview
  22. 8.4.3 Meda Pharmaceuticals Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Meda Pharmaceuticals Cancer Pain Therapeutics Product Portfolio
  24. 8.4.5 Meda Pharmaceuticals Recent Developments
  25. 8.5 Orexo
  26. 8.5.1 Orexo Company Information
  27. 8.5.2 Orexo Business Overview
  28. 8.5.3 Orexo Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Orexo Cancer Pain Therapeutics Product Portfolio
  30. 8.5.5 Orexo Recent Developments
  31. 8.6 ProStrakan Group
  32. 8.6.1 ProStrakan Group Company Information
  33. 8.6.2 ProStrakan Group Business Overview
  34. 8.6.3 ProStrakan Group Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ProStrakan Group Cancer Pain Therapeutics Product Portfolio
  36. 8.6.5 ProStrakan Group Recent Developments
  37. 8.7 WEX Pharmaceuticals
  38. 8.7.1 WEX Pharmaceuticals Company Information
  39. 8.7.2 WEX Pharmaceuticals Business Overview
  40. 8.7.3 WEX Pharmaceuticals Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 WEX Pharmaceuticals Cancer Pain Therapeutics Product Portfolio
  42. 8.7.5 WEX Pharmaceuticals Recent Developments
  43. 8.8 Eli-Lilly
  44. 8.8.1 Eli-Lilly Company Information
  45. 8.8.2 Eli-Lilly Business Overview
  46. 8.8.3 Eli-Lilly Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli-Lilly Cancer Pain Therapeutics Product Portfolio
  48. 8.8.5 Eli-Lilly Recent Developments
  49. 8.9 Johnson＆Johnson
  50. 8.9.1 Johnson＆Johnson Company Information
  51. 8.9.2 Johnson＆Johnson Business Overview
  52. 8.9.3 Johnson＆Johnson Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Johnson＆Johnson Cancer Pain Therapeutics Product Portfolio
  54. 8.9.5 Johnson＆Johnson Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Cancer Pain Therapeutics Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
  61. 8.11 Teva pharmaceuticals
  62. 8.11.1 Teva pharmaceuticals Company Information
  63. 8.11.2 Teva pharmaceuticals Business Overview
  64. 8.11.3 Teva pharmaceuticals Cancer Pain Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Teva pharmaceuticals Cancer Pain Therapeutics Product Portfolio
  66. 8.11.5 Teva pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Pain Therapeutics Value Chain Analysis
  2. 9.1.1 Cancer Pain Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Pain Therapeutics Production Mode & Process
  6. 9.2 Cancer Pain Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Pain Therapeutics Distributors
  9. 9.2.3 Cancer Pain Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst